Home > EADV Highlights
    • FILTER YOUR SEARCH
    Speciality:
    More Specialities

    • EADV Highlights

    Dermatological Conditions
    Martin Metz, EADV 2020 – Ligelizumab in Chronic Spontaneous Urticaria

    It was a delight to be able to discuss with Martin Metz (Charité – Universitätsmedizin Berlin, Berlin, Germany) the results of the 52-week extension study (NCT02649218), which investigated the monoclonal anti-IgE antibody, ligelizumab, in patients who had not achieved complete urticaria activity control with omalizumab. His abstract entitled ‘Efficacy of ligelizumab in chronic spontaneous urticaria […]

    Psoriasis
    Diamant Thaçi, EADV 2020: Long-term Efficacy of Tildrakizumab in Psoriasis

    It was an honour to talk with Prof. Diamant Thaçi (University of Lübeck, Lübeck, Germany) about the reSURFACE clinical studies and in particular, long-term data from reSURFACE 2 (NCT01729754).  Results from the study, which investigated the anti-IL-23p19 monoclonal antibody, tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis, were presented in the abstract entitled […]

    Psoriasis
    Lluís Puig, EADV 2020 – New Therapeutic Targets in Psoriasis

    We were delighted to be able to speak with Lluís Puig (Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain) about novel pathophysiology-based therapeutic agents in the treatment of psoriasis. His full presentation entitled ‘New therapeutic targets based on pathophysiology’ was presented at the EADV Virtual Congress 2020. Questions Could you give us a brief […]

    Dermatological Conditions
    Mehdi Rashighi, EADV 2020 – JAK inhibitors in Vitiligo

    We were delighted to catch up with Mehdi Rashighi (University of Massachusetts Medical School, Boston, MA, USA) to discuss the use of JAK inhibitors in the treatment of vitiligo. Questions What are the limitations of current therapeutic approaches for vitiligo? (0:26) What is the role of the JAK pathway in the pathogenesis of vitiligo? (0:56) […]

    Dermatological Conditions
    Giovanni Damiani, EADV 2020 – Highlights from the meeting

    Dr Giovanni Damiani (University of Milan; Clinical Dermatology, IRCCS Instituto Ortopedico Galeazzi) gave us some of his key highlights from EADV 2020. Disclosures: Dr Giovanni Damiani has no disclosures to report. Support: Interview and filming supported by Touch Medical Media. Filmed as highlights of the 29th EADV Virtual Congress 2020.  

    Psoriasis
    Linda Stein Gold, EADV 2020 – Roflumilast Cream in Chronic Plaque Psoriasis

    We caught up with Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) to discuss the results of the phase 2B study of roflumilast cream in adults with chronic plaque psoriasis (ClinicalTrials.gov identifier: NCT03638258). Questions 1. What are the limitations of current topical therapies for chronic plaque psoriasis? (0:06) 2. What is the mechanism […]

    Axial Spondyloarthritis
    Peter C Taylor, EADV 2020 – Seronegative Spondyloarthropathies and the IL23/IL17 Axis

    Following his related presentation at the EADV 2020 Virtual Congress, our Editor-in-Chief, Peter C Taylor (University of Oxford, Oxford, UK), took the time to speak with us more about the IL-23 pathway in seronegative spondyloarthropathies. Questions What are the seronegative spondyloarthropathies? (0:06) What have we learnt in recent years, based on therapeutic advances in this area? […]

    Psoriasis
    Kim Papp, EADV 2020 – Sonelokinab for Chronic Plaque Psoriasis

    We were delighted to discuss with Kim Papp (Probity Medical Research, Waterloo, ON, Canada) the results of the phase IIb study assessing the efficacy, safety and tolerability of sonelokinab (M1095), and IL-17 A/F nanobody, in patients with moderate-to-severe chronic plaques psoriasis (Clinical Trial Identifier: NCT03384745) Questions  What are the major unmet needs in the treatment […]

    Psoriasis
    Tiago Torres, EADV 2020 – The IL-23 Pathway in Psoriasis

    We were delighted to have the opportunity to speak with Expert Faculty member Tiago Torres (Centro Hospitalar Universitário do Porto, Portugal) about the biology of the IL-23 pathway in psoriasis and the therapeutic use of IL-23 inhibitors. Questions Could you give us a brief overview of the role of the IL-23 in the pathogenesis of psoriasis? […]

    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72